Hematology-American Society of Hematology Education Program

Papers
(The TQCC of Hematology-American Society of Hematology Education Program is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?100
The varieties of therapeutic experience: navigating treatment options for patients with PNH94
Mastocytosis demystified67
On the horizon: upcoming new agents for the management of ITP64
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?54
Labor and delivery: DIC, HELLP, preeclampsia45
Bispecific antibody therapies45
Challenges and opportunities in the long-term management of immune-mediated TTP44
Inpatient recognition and management of HLH36
Recognizing, defining, and managing CAR-T hematologic toxicities34
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment32
Anticoagulation at the end of life: whether, when, and how to treat31
Your chemo is no good here: management of high-risk MCL30
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma29
Neurological manifestations of MGUS29
Has PD-1 blockade changed the standard of care for cHL?28
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma28
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient28
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL27
Where do immunotherapies stand in management of acute leukemia in adults?27
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease27
New therapies in hemophilia: extend the half-life, mimic, or rebalance?27
Optimizing outcomes in secondary AML26
Troubleshooting heparin resistance26
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia25
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies25
New approaches to tackle cytopenic myelofibrosis24
Fitness and frailty in myeloma24
How to assess hemostasis in patients with severe liver disease24
Donor selection, graft engineering, and dosing oh my!24
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?24
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL24
Divergent paths: management of early relapsed follicular lymphoma23
Selecting initial therapy in CLL23
BV and beyond: how to incorporate novel agents into PTCL management23
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?22
MGCS: where do we stand today?22
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease22
Incorporating novel agents into frontline treatment of Hodgkin lymphoma21
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores20
What's new in hereditary hemorrhagic telangiectasia?20
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?20
Consumptive coagulopathy in the ICU20
Hematology 2022—what is complete HLA match in 2022?19
Management of limited-stage Hodgkin lymphoma19
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?19
How to manage hemostasis in patients with liver disease during interventions19
How to diagnose and manage antiphospholipid syndrome19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity19
Management of TKI-resistant chronic phase CML19
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation19
Demystifying autoimmune HIT: what it is, when to test, and how to treat19
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 20218
Management of marginal zone lymphomas18
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies18
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma17
CNS prophylaxis in aggressive B-cell lymphoma17
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL17
Thrombosis questions from the inpatient wards17
Transplant in AML with measurable residual disease: proceed or defer?17
Special considerations in GI bleeding in VWD patients17
Atypical CML: diagnosis and treatment17
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?17
Nontransplant treatment approaches for myeloid neoplasm with mutated TP5316
Organ function indications and potential improvements following curative therapy for sickle cell disease16
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy16
Management of autoimmune hemolytic anemia16
Alloimmunization and hyperhemolysis in sickle cell disease16
Approaches to management of HIT in complex scenarios, including cardiac surgery16
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing16
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment15
Pregnancy management for patients with bleeding disorders15
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma15
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment15
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?14
Cytoreduction for ET and PV: who, what, when, and how?14
Pegylated interferon: the who, why, and how14
Ph− ALL: immunotherapy in upfront treatment14
Treatment of VTE in the thrombocytopenic cancer patient14
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease14
POEMS syndrome: diagnosis, treatments, and outcomes14
Thrombocytopenia in pregnancy14
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms14
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes14
What makes a pediatric or young adult patient an appropriate transplant candidate?14
What is the ideal approach—doublet, triplet, or quadruplet(s)?13
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS13
Clinical manifestations of telomere biology disorders in adults13
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax13
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS13
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era13
Monoclonal gammopathy of renal significance from a hematologic perspective13
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?13
Should we use bisphosphonates to treat bone complications in sickle cell disease?13
Future directions in transplantation for aplastic anemia13
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?13
Managing pregnancy in patients with sickle cell disease from a transfusion perspective13
Next-generation therapy for lower-risk MDS13
0.17244100570679